BioWorld Asia

Dec. 14, 2005

BioAlliance Pharma Completes Initial Public Offering For EUR30M

PARIS - BioAlliance Pharma SA completed its initial public offering on Eurolist Compartment C of the Euronext stock exchange in Paris, raising gross proceeds of some €30 million (US$35.9 million). (BioWorld International) Read More

Domantis' Valuation Higher For £17M Third Financing

Dutch Team Finds Aspects Of Cell Cycle Checkpoints

Zealand Pharma Learning Lessons From Pulled IPO

Group Of GMO Crop Raiders Acquitted By French Court

Cellartis Brings In EUR 8M For Embryonic Stem Cell Work

Alizyme Reports Positive Data For Cetilistat, Plans Phase III

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 20, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

Silhouette of head and brainwith fractal art

ATAI-dyed Lilly tees up in psychedelics, finds $3.8B fit

BioWorld

Rumblings that psychedelic treatments would soon be ready for prime time gained credence aplenty, and shares of Ataibeckley Inc. (NASDAQ:ATAI) ended July 16 at...